CRI Report: Oncology Precision Medicine Market to reach $1,28,891.6 million by 2031
The premium market intelligence report published by Our Research Team on the title Global Oncology Precision Medicine Market highlights that the market is projected to reach $1,28,891.6 million by 2031. The study also highlights that the market is set to witness a CAGR of 10.05% during the forecast period 2021-2031.
The precision medicine concept is a systematic process aiming to achieve victory over a disease such as cancer. Cancer is the major focus of various precision medicine initiatives, and precision oncology centers around matching the most accurate and precise treatment to each cancer patient on the basis of an individual’s matching genetic profile that could ultimately let them benefit from the treatment offered.
The comprehensive study covers the following:
• Market numbers on micro-segments that are influencing the market
• Market share analysis for more than 22 companies
• Study of data of more than 30 companies
Who should buy this report?
• Oncology precision medicine manufacturers, who are planning to invest in one of the large established markets
• Companies involved in the ecosystem of oncology precision medicine
• Companies in the precision medicine market
• Companies involved in developing treatment regimens for cancer
To gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include ecosystem, application, and region. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study.
The premium market intelligence by Our Research Team also highlights the opportunities existing in the market, including the high scope for adoption of precision medicine for cancer treatment in emerging nations, increased use of applied sciences, and providing a solution for the treatment of chronic diseases. The study is majorly centered on the sub-segments and micro-segments of the different commercialized products in the market.
To emphasize the dominance of the North America segment in the regional segmentation of the global oncology precision medicine market in 2020 and 2031, Nitish Kumar Singh, Principal Analyst – Our Research Team, states, “North America is the leading contributor to the global oncology precision medicine market. It contributed approximately 35.30% to the global market value in 2020. This region is anticipated to grow at a CAGR of 9.73% during the forecast period 2021-2031 and will continue dominating the global market in 2031. However, the Asia-Pacific region is expected to grow at an impressive CAGR of 11.53% during the forecast period 2021- 2031.”
Key insights are drawn from in-depth interviews with the key opinion leaders of more than 22 leading companies, market participants, and vendors. The key players profiled in the report include Pacific Biosciences of California, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Illumina, Inc., QIAGEN, Bio-Rad Laboratories, Inc., PerkinElmer Inc, Novartis AG, Myriad Genetics, OPKO Health, Inc., Quest Diagnostics, Gilead Sciences, MDx Health, Inc., Abbott Laboratories, F-Hoffmann, La. Roche Ltd., BGI Group, Almac Group Ltd., Asuragen, Inc., and Prelude Therapeutics, AceTech, Biosplice Therapeutics, and Flatiron Health.
The study also offers strategic recommendations that can help organizations track various products, trends, and applications that are changing the dynamics of the market. The recommendations by Our Research Team also offer bespoke research services to help organizations meet their objectives.
How can market intelligence on oncology precision medicine add value to an organization’s decision-making process?
• Offers detailed information on the future perspective of the emerging as well as established players
• Offers go-to-market strategies for the different source type
• Supports in diversifying the product portfolio based on risk and progression of application in oncology precision medicine
• Helps in analyzing technological substitutes and comparing the specification of various ecosystems and applications
• Offers tailor-made solutions based on the throughput of different consumers
• Assists in exploring the newer application
• Supports in analyzing the competitors’ funding scenario
• Helps in understanding the involvement of government health organizations such as the U.S. Food and Drug Administration (U.S. FDA)
• Aids in understanding the new trends in the precision oncology industry
Insightful Questions Covered to Enable Companies to take Strategic Decisions
• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment?
• What are the major market drivers, restraints, and opportunities in the global oncology precision medicine market?
• What are the underlying structures resulting in the emerging trends within the global oncology precision medicine market?
• How is each segment of the global oncology precision medicine market expected to grow during the forecast period, and what will be the expected revenue generated by each of the segments by the end of 2031?
• What are the key developmental strategies implemented by the major players to sustain in the competitive market?
• What are the key regulatory implications in developed and developing regions for oncology precision medicine?
• Who are the leading players with significant offerings to the global oncology precision medicine market? What is the current market dominance for each of these leading players?
• What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2021-2031? Which ecosystem in the oncology precision medicine type has the most promising growth?
• What are the major applications employed in the global oncology precision medicine market? Which is the dominating application?
• Who are the key manufacturers in the global oncology precision medicine market, and what are their contributions? Also, what is the growth potential of each major oncology precision medicine manufacturer?
• What is the scope of the global oncology precision medicine market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World? Which oncology precision medicine technology and end user dominate these regions?
• What are the emerging trends in the global oncology precision medicine market? How are these trends revolutionizing the diagnostic procedure?
• Which technologies are anticipated to break through the oncology precision medicine regime?
• Which companies are anticipated to be highly disruptive in the future and why?
• What are the regulatory procedures that are required to unify the approval process for the emerging oncology precision medicine market? How will these enhance the reimbursement scenario?
• What are the gaps in regularizing oncology precision medicine adoption in regular healthcare routines? How are these gaps being tackled?
Buy the report: Oncology Precision Medicine Market – A Global and Regional Analysis: Focus on Ecosystem and Application – Analysis and Forecast, 2020-2031